致康胶囊对急性创伤患者血液流变学的影响

目的：观察致康胶囊治疗急性创伤患者过程中血液流变学指标的变化。方法：急性创伤患者40例，随机分成治疗组和对照组各20例。两组常规治疗相同。治疗组加服致康胶囊每次2～4粒，tid，于治疗前及治疗后第7天检测血液流变学指标。结果：与对照组相比，治疗组全血低切粘度、全血高切粘度、血浆粘度、红细胞聚集指数、血沉、红细胞变形指数于治疗后均有显著改善(P＜0.05或＜0.01)。结论：致康胶囊可降低急性创伤患者的血液粘度，对预防创伤后血栓形成有重要作用。     

刺五加注射液治疗急性脑梗塞28例

目的:探讨刺五加注射液治疗脑梗塞的疗效。方法:将56例脑梗塞患者随机分为治疗组28例和对照组28例,两组均予常规脱水、脑组织保护剂治疗,治疗组在此基础上加用刺五加注射液静脉滴注。结果:两组治愈率显效+治愈率比较,有显著性差异;治疗组治疗前后全血粘度、红细胞压积、血浆粘度、还原比粘度、纤维蛋白原均显著降低（P<0.01）,血沉显著增高（P<0.05）;对照组全血粘度和血浆粘度显著降低（P<0.01）。结论:刺五加注射液治疗脑梗塞,疗效明显优于单用西药。     

光量子血疗对寻常型银屑病血液流变学的影响

目的探讨光量子血疗对银屑病患者血液流变学的改变和临床意义。方法对120例寻常型银屑病患者治疗前后测定全血粘度,血浆粘度,全血还原粘度,红细胞压积等血流变指标。结果光量子血疗组患者的全血粘度、血浆粘度、红细胞压积、全血还原粘度与丹参组对照相比,显著下降,光量子血疗较丹参组显著改善血液流变学状况,临床疗效比较有显著统计学差异（P〈0．01或P〈0．05）。结论光量子血疗较丹参治疗寻常型银屑病效果更佳,疗效更确切。     

舒血宁注射液治疗肺心病高黏血症的效果及对血流变指标变化的影响

目的探讨舒血宁注射液治疗肺心病高黏血症的临床效果及对血液流变学指标的影响。方法选取我院2014年3月~2016年3月收治的肺心病高黏血症患者120例,随机分为实验组和对照组,对照组60例,采用常规治疗;实验组60例,在常规治疗的基础上注射舒血宁注射液。比较两组患者症状、体征、总有效率等,比较两组患者治疗前后的血液流变学指标,如红细胞数、全血粘度、红细胞压积、纤维蛋白原含量等。结果实验组总有效率明显大于对照组,差异有统计学意义(P0.05);两组患者治疗后红细胞数、全血粘度、红细胞压积、纤维蛋白原含量等指标均较治疗前有所改善,且差异具有统计学意义(P0.05);实验组治疗后的红细胞数、全血粘度、红细胞压积、纤维蛋白原含量等指标较对照组治疗后显著降低,差异有统计学意义(P0.05)。结论舒血宁注射液对于肺心病高黏血症具有良好的临床效果,且能显著改善患者血液流变学指标。     

丹参多酚酸盐对冠心病稳定型心绞痛患者血小板功能的影响

目的:探讨丹参多酚酸盐对冠心病稳定型心绞痛患者血小板功能的影响。方法:选取我院2010年1月-2014年1月收治入院的冠心病稳定型心绞痛患者200例,根据治疗方法不同分为两组,其中对照组100例采用常规抗血小板聚集、抗凝和抗缺血等药物治疗,观察组100例在常规治疗基础上采用丹参多酚酸盐治疗,测定两组患者治疗前、治疗后两周采集两组患者静脉血,采用比浊法测定血小板聚集率(MPAR),同时监测血流变指标。结果:观察组治疗后心功能改善显效51例,有效40例,无效9例,治疗总有效率为91.0%(91/100);对照组治疗24周后心功能改善显效48例,有效22例,无效30例,治疗总有效率为70.0%(70/100),两组总有效率比较差异有统计学意义(X2=5.638,P<0.05);两组患者治疗后MPAR、全血粘度高切、全血粘度低切、血浆粘度、红细胞聚集指数等指标均明显低于治疗前,且差异有统计学意义(P<0.05);观察组患者治疗后MPAR、全血粘度高切、全血粘度低切、血浆粘度、红细胞聚集指数等指标均明显低于对照组治疗后,且差异有统计学意义(P<0.05)。结论:丹参多酚酸盐注射液可显著降低冠心病稳定型心绞痛患者血小板聚集功能,改善其血液流变学指标,有效缓解症状,减少不良事件的发生。     

蕲蛇酶对糖尿病合并脑梗死高黏血症的影响

目的观察蕲蛇酶对糖尿病合并脑梗死患者血液流变学指标的影响。方法以自身对照的方法,观察58例糖尿病合并脑梗死患者接受治疗前后的血液流变学指标的变化。结果治疗前后,男性组红细胞压积、低切变率全血粘度、血浆粘度、红细胞变形能力及纤维蛋白原均有明显变化,存在显著差异（P〈0．05）,特别是低切变率下的红细胞变形能力的变化具有显著差异（P〈0．01）;女性组血浆粘度、全血粘度、红细胞变形能力及纤维蛋白原均有明显变化,具有显著差异（P〈0．05）。结论蕲蛇酶能显著降低纤维蛋白原及低切变率下的全血粘度和血浆粘度,改善脑缺血,并缓解因梗死引起的中枢与肢体的临床症状。     

银杏蜜环口服溶液治疗慢性脑供血不足的疗效观察

目的分析银杏蜜环口服溶液在慢性脑供血不足治疗中的应用效果。方法100例慢性脑供血不足患者,按照随机颜色球抽取法分为参照组及研究组,各50例。参照组给予氟桂利嗪胶囊联合阿司匹林肠溶片治疗,研究组在参照组基础上给予银杏蜜环口服溶液治疗。比较两组治疗效果及血液各项指标。结果研究组不良反应发生率6%低于参照组的44%,差异具有统计学意义(P<0.05)。治疗后,两组全血高切粘度、全血中切粘度、全血低切粘度、血浆粘度、红细胞聚集指数、红细胞变形指数均较治疗前降低,且研究组低于参照组,差异具有统计学意义(P<0.05)。结论应用银杏蜜环口服溶液对慢性脑供血不足进行治疗,能够有效的提高治疗效果,改善血液流变学状态,具有推广价值。     

综合应用肝素钠治疗肺心病78例临床分析

目的　观察肝素钠(苏可诺)治疗肺心病的临床疗效及对血液流变学的影响。方法　采取随机抽样,观察78例肺心病患者,其中治疗组39例,对照组39例。结果　治疗组总有效率为94 . 87%,治疗前后全血粘度、血脂粘度、纤维蛋白原、红细胞压积均明显下降(P <0 . 0 5 ) ,无1例继发出血。结论　肝素钠治疗肺心病效果较好,副作用少。     

综合应用肝素钠治疗肺心病78例临床分析

目的观察肝素钠(苏可诺)治疗肺心病的临床疗效及对血液流变学的影响.方法采取随机抽样,观察78例肺心病患者,其中治疗组39例,对照组39例.结果治疗组总有效率为94.87%,治疗前后全血粘度、血脂粘度、纤维蛋白原、红细胞压积均明显下降(P＜0.05),无1例继发出血.结论肝素钠治疗肺心病效果较好,副作用少.     

马来酸桂哌齐特治疗老年人椎-基底动脉供血不足的疗效观察

目的观察马来酸桂哌齐特对老年人椎-基底动脉供血不足的疗效及对血液流变学的影响。方法采用随机、对照方法将患者分为治疗组38例,马来酸桂哌齐特注射液治疗;对照组32例,用丹参粉剂治疗。结果治疗组总有效率为92%,高于对照组63%(P<0.01)。治疗组用药后全血粘度高切、低切、血浆粘度、红细胞比容、红细胞聚集指数均用药前下降。结论马来酸桂哌齐特可有效改善老年人椎-基底动脉供血不足的症状及体征,且副作用少。     

氯沙坦对高血压伴心房纤颤患者脑卒中一级预防的效果研究

目的 观察长期口服氯沙坦对高血压伴心房纤颤(房颤)患者脑卒中一级预防的效果.方法 采用前瞻性随机对照研究方法,将180例高血压伴房颤患者随机分为观察组和对照组,每组90例,分别予以口服氯沙坦和美托洛尔治疗,治疗时间均为3年.观察血压、脉压变化以及脑卒中发生率和因心血管事件的病死率.结果 治疗3年后,两组患者血压均显著下降(均P＜0.01).但治疗组血压波动幅度、脉压均明显降低(均P＜0.01),而对照组无明显变化(P＞0.05).观察组脑卒中发生率、心肌梗死发生率以及因心血管事件病死率分别为22.2％、10.0％和13.3％,与对照组的70.0％、40.0％和44.4％相比,差异均有统计学意义(均P＜0.01).结论 氯沙坦与美托洛尔比较,降压效果相同,但对脑卒中一级预防的效果明显优于美托洛尔.     

都梁软胶囊联合尼莫地平治疗偏头痛的临床研究

目的观察都梁软胶囊联合尼莫地平治疗偏头痛的临床效果。方法将68例偏头痛患者随机分为治疗组和对照组,每组34例。治疗组用都梁软胶囊加尼莫地平治疗,对照组用尼莫地平治疗。15d后观察两组的临床疗效、头痛程度及血液流变学的变化。结果治疗组的总有效率为94．12％,高于对照组的76．47％（P〈0．05）。两组治疗后头痛程度均减轻,且治疗组效果更明显,与对照组比较差异有统计学意义（P〈0．05）。两组治疗后血液流变学比较,差异有统计学意义（P〈0．05）。结论都梁软胶囊联合尼莫地平对偏头痛的治疗效果显著。     

Antioxidant effect of thiamine on acutely alcoholized rats and lack of efficacy using thiamine or glucose to reduce blood alcohol content

Although there is no consensus about the use of glucose and thiamine for the treatment of acute ethanol intoxication, this is a routine practice in many countries. Our objective was to determine the efficacy of this treatment and the changes it causes in the antioxidant status of the liver. Male Wistar rats were intoxicated with an ethanol dose of 5 g/kg and divided into three groups: ethanol (EtOH; untreated), EtOH+G (treated with glucose), and EtOH+B1 (treated with thiamine). Blood and urinary ethanol as well as hepatic malondialdehyde, reduced glutathione and vitamin E were determined in all animals. Blood alcohol levels did not differ between groups, although urinary excretion was about four times higher in the group treated with thiamine (EtOH+B1). The malondialdehyde, reduced glutathione and vitamin E values used here as parameters of the antioxidant system of the liver showed improvement for the thiamine-treated group (EtOH+B1). Treatment with glucose or thiamine was ineffective in reducing blood alcohol levels in rats with acute ethanol intoxication. However, the beneficial effect of thiamine as an antioxidant for ethanol metabolism was demonstrated. Further investigations are necessary to clarify the urinary excretion of ethanol reported here for the first time and the possibility of using thiamine as an antioxidant in situations of chronic alcohol use.     

阿托伐他汀序贯疗法对不稳定型心绞痛PCI术后临床疗效影响

目的评价阿托伐他汀序贯疗法对不稳定型心绞痛患者PCI术后高敏C-反应蛋白（hs—CRP）、血脂、临床预后及安全性的影响。方法阿托伐他汀序贯治疗组（观察组）80例,常规阿托伐他汀治疗组（对照组）76例,观察组入院给予阿托伐他汀80mg顿服,PCI术前2h再次顿服阿托伐他汀40rag,术后继续服用阿托伐他汀40mg／d,1个月之后减为阿托伐他汀20mg／d;对照组阿托伐他汀Z0mg／次,1次／d,观察PCI治疗前后血脂、hs—CRP水平及不良事件发生情况。结果两组PCI术前、后TC、LDL—C、TG及hs—CRP水平与治疗前相比,均有降低（P〈0．05）;观察组与对照组相比,治疗后观察组上述指标降低更明显（P〈0．05）;观察组不良事件也低于对照组（P〈0．05）。结论阿托伐他汀续贯疗法可以进一步强化调脂,降低hs—CRP水平,降低不良事件,改善患者预后。     

重组人生长激素对败血症休克大鼠微循环功能障碍的影响

目的观察重组人生长激素(rhGH)对败血症休克大鼠微循环功能障碍的影响。方法ipE.coli复制大鼠败血症休克模型。采用微循环观测系统及激光多普勒观测正常对照组(C组)、败血症休克组(S组)及rhGH治疗组(T组)第1、3天的肠道微循环、耳廓血流量等指标的变化情况。结果S组大鼠肠道微循环血流明显减慢甚至淤滞,血管明显扩张,血管数、管袢数及功能血管数明显减少,尤以第1天时最为明显;T组大鼠肠道微循环血液流速、血管数及功能血管数均明显高于S组,与C组比较无显著性差异。S组大鼠耳廓血流量在各时点均显著低于C组、T组水平,但T组与C组比较无明显差异。结论rhGH可明显改善败血症休克大鼠的微循环功能障碍。     

氯沙坦钾治疗原发性高血压75例疗效分析

目的：评价氯沙坦钾治疗高血压的疗效。方法：将150例符合入组条件的原发性高血压患者随机分为氯沙坦钾治疗组和对照组（卡托普利治疗）,每组75例。治疗组服用氯沙坦钾50mg,1次／d,对照组服用卡托普利25mg,2次,d,共观察8周。观察各组的治疗效果和不良反应情况。结果：治疗组和对照组患者在治疗前后血压都下降平稳,治疗组和对照组患者血压下降没有明显的差异。对照组和治疗组患者的心率和生化指标没有明显改变,对照组中有2例出现显著的干咳,不能耐受实验,而治疗组没有这种现象。结论：氯沙坦钾治疗原发性高血压安全、有效,其发生不良反应的可能性较卡托普利显著降低。     

银杏叶对原发性高血压早期肾损害的临床研究

目的：探讨银杏叶提取物（Ginkgobiboa leaf tablet GLT）对原发性高血压患者早期肾损害的影响。方法：选择80例原发性高血压合并有微量蛋白尿患者,随机分为对照组（n=40）和治疗组（n=40）,对照组给予福辛普利钠10mg,po,qd,治疗组在对照组治疗的基础上加用GLT19．2mg,po,tid,治疗4月,观察治疗前后血压及尿微量蛋白值,并进行比较。结果：两组治疗后血压均明显下降（P〈0．01）,微量蛋白尿排泄均减少（P〈0．01）,但治疗组与对照组比较差异显著（P〈0．05）,且治疗组TG、Tc、Cr下降（P〈0．05）,HDL升高（P〈0．01）,与对照组比较,P〈0．05。结论：福辛普利钠和GLT可有效减少高血压患者微量蛋白尿排泄,防治早期肾损害。     

Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor

1. Over the course of treatment with angiotensin-converting enzyme inhibitor (ACEI), plasma levels of aldosterone have been shown to increase and this increase would blunt the effectiveness of the ACEI (aldosterone escape phenomenon). 2. In the present study, we assessed a potential renal benefit of additional aldosterone blockade with spironolactone in hypertensive diabetic patients treated with ACEI showing the phase of aldosterone escape. 3. The present clinical study was a randomized prospective study to assess difference between the clinical effects of spironolactone and furosemide. Thirty hypertensive type II diabetics (DM2) with a urinary alubumin:creatinine ratio (ACR) above 30 mg/g creatinine (showing albuminuria) and plasma B-type natriuretic peptide (BNP) levels above 100 pg/mL (showing mild heart failure) were treated with an ACEI (imidapril 5 mg/day) for 1 year and then randomly divided into two groups, one group receiving additional spironolactone (25 mg/day) treatment and the other receiving furosemide (20 mg/day) treatment. Blood pressure, ACR and plasma BNP levels were monitored in both groups. 4. Treatment with the ACEI reduced ACR initially but, in 1 year, ACR tended to increase. Additional spironolactone treatment progressively reduced ACR, whereas furosemide treatment did not show any effect. Plasma BNP levels were reduced by ACEI and were further reduced by additional spironolactone treatment, but not furosemide treatment. Blood pressure levels in both groups were comparable. 5. In conclusion, additional therapy with spironolactone in ACEI treatment exerts a renoprotective, as well as cardioprotective, effect in hypertensive diabetes.     

Evaluation of hypoglycemic effect of Morus alba in an animal model

Objective:

The objective of the present investigation was to evaluate the therapeutic efficacy of mulberry leaves in an animal model of diabetes.

Materials and Methods:

Animals were treated with mulberry leaf extract 400 mg and 600 mg/kg body weight for 35 days. Blood glucose, glycosylated hemoglobin, triglyceride, LDL, VLDL, HDL, blood urea, cholesterol, number of β cells, and diameter of the islets of Langerhans were measured at the beginning and at the end of the experiment.

Results:

Blood glucose level and other parameters (except HDL) were elevated in the diabetic group, but were brought to control group level in the diabetic group treated with 600 mg/kg body weight of mulberry leaf extract. The diameter of the islets and the number of β cells were reduced in the diabetic group; both parameters were brought to control group level after treatment with mulberry leaf extract.

Conclusion:

Mulberry leaf extract, at a dose of 600 mg/kg body weight, has therapeutic effects in diabetes-induced Wistar rats and can restore the diminished β cell numbers.     

Hepatoprotective effect of tempol on oxidative toxic stress in STZ-induced diabetic rats

Tempol is a synthetic antioxidant. Since many studies revealed the protective effect of antioxidants on liver, current study was performed to assess the hepatoprotective effects of tempol on streptozotocin induced diabetic rats. Blood glucose, oxidative toxic stress (OTS) biomarkers and liver enzymes were measured. Findings showed that tempol significantly decreased serum levels of glucose in tempol treated group. Also treatment with tempol significantly reduced AST and ALT compared to diabetic control group (p?相似文献